Takeda Pharmaceutical Co. Ltd. is the latest in a string of pharmaceutical manufacturers investing in molecular glue degraders through dealmaking. The company announced a collaboration with Shanghai-based Degron Therapeutics on 23 May to discover and develop novel molecular glue degraders (MGDs) for multiple targets across oncology, neuroscience and inflammation.
Takeda Goes In On Molecular Glue Degraders With Degron Deal
The company will pay $1.2bn in upfront and milestone fees to access Degron’s GlueXplorer platform across multiple therapeutic areas.
More from Deals
More from Business
• By
As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.
• By
Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.
• By
MariTide could give Amgen a big boost if successful in obesity, but the drug just entered Phase III. Even so, Q1 revenue rose 9% to $8.15bn and more growth is expected in 2025.